TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis → [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad) Free ONC Stock Alerts C$1.63 -0.06 (-3.55%) (As of 10:25 AM ET) Add Compare Share Share Today's RangeC$1.63▼C$1.6650-Day RangeC$1.24▼C$1.6952-Week RangeC$1.20▼C$4.49Volume20,181 shsAverage Volume73,275 shsMarket CapitalizationC$122.93 millionP/E RatioN/ADividend Yield0.31%Price TargetC$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside255.0% UpsideC$6.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.66Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 stars 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ONC. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONC. Previous Next 1.9 News and Social Media Coverage News SentimentOncolytics Biotech has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.Search Interest2 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.24% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.98% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Oncolytics Biotech Stock (TSE:ONC)Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesMay 10, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational HighlightsMay 10, 2024 | americanbankingnews.comOncolytics Biotech (TSE:ONC) Share Price Crosses Above 200-Day Moving Average of $1.68May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 9, 2024 | msn.comONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deFN Media Group: Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036May 9, 2024 | ca.finance.yahoo.comStocks in play: Oncolytics Biotech Inc.May 9, 2024 | finance.yahoo.comOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | finanznachrichten.deUSA News Group: Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 8, 2024 | finance.yahoo.comOncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | americanbankingnews.comOncolytics Biotech (ONC) Scheduled to Post Earnings on ThursdayApril 11, 2024 | ca.finance.yahoo.comStocks in play: Oncolytics Biotech® Inc.April 11, 2024 | finance.yahoo.comOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAApril 10, 2024 | markets.businessinsider.comTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024March 16, 2024 | theglobeandmail.comClosing Bell: Oncolytics Bio down on Friday (ONC)March 11, 2024 | msn.comFutures Retreat SharplyMarch 6, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANMarch 6, 2024 | finanznachrichten.deEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningMarch 6, 2024 | benzinga.comA Preview Of Oncolytics Biotech's EarningsMarch 2, 2024 | morningstar.comOncolytics Biotech Inc ONCFebruary 15, 2024 | markets.businessinsider.comReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s PipelineFebruary 15, 2024 | finance.yahoo.comCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation TreatmentsFebruary 14, 2024 | theglobeandmail.comAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New TherapiesFebruary 7, 2024 | finanznachrichten.deUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024January 31, 2024 | finance.yahoo.comKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic VirusesJanuary 6, 2024 | benzinga.comOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, PredictionsDecember 14, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)See More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$6.00 High Stock Price TargetC$9.00 Low Stock Price TargetC$3.00 Potential Upside/Downside+255.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-27,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.66% Return on Assets-55.47% Debt Debt-to-Equity Ratio1.54 Current Ratio9.01 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.40 per share Price / Cash Flow4.22 Book ValueC$0.37 per share Price / Book4.57Miscellaneous Outstanding Shares75,420,000Free FloatN/AMarket CapC$127.46 million OptionableNot Optionable Beta1.49 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz Levin B.S.N.R.N., Vice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsSernovaTSE:SVAScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHIntelGenx TechnologiesCVE:IGXView All Competitors ONC Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 3 Wall Street research analysts have issued 12-month target prices for Oncolytics Biotech's shares. Their ONC share price targets range from C$3.00 to C$9.00. On average, they anticipate the company's stock price to reach C$6.00 in the next twelve months. This suggests a possible upside of 255.0% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts. How have ONC shares performed in 2024? Oncolytics Biotech's stock was trading at C$1.79 at the beginning of 2024. Since then, ONC shares have decreased by 5.6% and is now trading at C$1.69. View the best growth stocks for 2024 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ONC earnings forecast. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) announced its earnings results on Thursday, March, 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR). How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ONC) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
